The drug sensitivity of cyclosporine A combined with antineoplastic drugs in retinoblastoma in vitro.
OBJECTIVE
To study cyclosporine A inhibition on the fresh retinoblastoma cells in vitro and increasing the drug sensitivity after combined with different antineoplastic drugs.


METHODS
To study the growth curve of cyclosporine A on 27 samples of primary retinoblastoma cells by MTT assay and to study the change of the drug sensitivity by cyclosporine A combined with seven antineoplastic drugs.


RESULTS
The average IC50 of cyclosporine A on the 27 retinoblastoma cells is 67.81microg/ ml and the average inhibitive rate of these samples is 26.1% when cyclosporine A is in the concentration of 2microg/ml. The inhibitive rates all got improved after the seven antineoplastic drugs combined with cyclosporine A and the increasing average inhibitive rate is more than 5.


CONCLUSIONS
Cyclosporine A can inhibit retinoblastoma cells in vitro and its inhibitive effect is dose dependent. Moreover it can enhance the inhibition of multiple antineoplastic drugs on retinoblastoma cells.
Liu
Wanli
W
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.
Wu
Zhongyao
Z
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000187:drug effects; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016572:Cyclosporine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004357:Drug Synergism; D006801:Humans; D012175:Retinoblastoma / Q000473:pathology*; D014407:Tumor Cells, Cultured
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D016572:Cyclosporine